A Phase I/II, Multicentre, Open-label, Dose Escalation and Randomized Trial of BI 836858 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes
Phase of Trial: Phase I/II
Latest Information Update: 23 Oct 2017
At a glance
- Drugs BI 836858 (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 26 Jun 2017 Planned End Date changed from 8 Nov 2019 to 15 Jul 2020.
- 03 Nov 2015 Planned End Date changed from 1 Aug 2018 to 1 Nov 2019 as reported by ClinicalTrials.gov.
- 03 Nov 2015 Planned primary completion date changed from 1 Aug 2018 to 1 Nov 2018m as reported by ClinicalTrials.gov.